ALSO NOTED: NBTY buys Solgar; Ind-Swift expanding; Shire gets new Adderall letter; and much more...

> NBTY is buying Wyeth's Solgar Vitamin and Herb for $115 million. Story

> India's Ind-Swift is expanding its manufacturing operations. Article

> The UK's Shire Pharmaceuticals has received a second letter from Teva covering an amendment to its ANDA on a generic version of Adderall XR. Story

> Toronto-based Lorus says its cancer drug Virulizin has been granted orphan drug status in the European Union. Release

> Evotec has received its first milestone from its partnership with Boehringer Ingelheim. Release

> San Diego-based TorreyPines Therapeutics has filed an IND for NGX267, the first of several compounds in the company's product pipeline that are designed to treat Alzheimer's disease. Release

And Finally... The New York Times examines the widespread incidence of shingles and breakthrough research on a vaccine that could cure it for a majority of patients. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.